GAA-creatine in elderly
The objective of this pilot trial was to evaluate the effects of 8-week GAA-creatine supplementation versus placebo on skeletal muscle and brain creatine levels, cognitive function, functional outcomes, and safety biomarkers in men and women aged 65 years and older. Twenty-one healthy elderly individuals (age 69.6 ± 4.9 years, body mass index 27.6 ± 4.2 kg/m2; 13 women) were randomly assigned to receive a GAA-creatine mixture (2 g/day of GAA and 2 g/day of creatine) or placebo (inulin) for 8 weeks; the washout period lasted for 4 weeks to prevent any residual effects of interventions across study periods. MRS revealed that GAA-creatine significantly increased brain and muscle creatine levels in individual regions of interest from baseline to 8-week follow-up, as compared to placebo (p < 0.05). The mixture was significantly superior to placebo to improve gait speed test, 5XSST, and TUGT performance at post-administration (p < 0.01), while no differences were found between interventions for MoCA and SarQoL scores (p > 0.05). Although more studies are needed to corroborate our preliminary findings, GAA-creatine might be recognized as a nutritional intervention with the potential to tackle compromised tissue bioenergetics and functional impairments associated with aging.
Seper V, Korovljev D, Todorovic N, Stajer V, Ostojic J, Nesic N, Ostojic SM. Guanidinoacetate-Creatine Supplementation Improves Functional Performance and Muscle and Brain Bioenergetics in the Elderly: A Pilot Study. Ann Nutr Metab. 2021 Aug 30;77(4):244-247.